Trials / Completed
CompletedNCT05315882
Cytomegalovirus Infection After HSCT and PT-CY as GVHD Prophylaxis >> GVHD PROPHYLAXIS ERA
Cytomegalovirus Infection, Indirect Effects and Mortality in Hematopoietic Stem Cell Transplantation With Cyclophosphamide Post-transplant
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 300 (actual)
- Sponsor
- Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
Multicentre, observational, retrospective study to analyze the differences in CMVi pattern and recurrences between two groups of allogeneic HSCT patients (haplo vs no haplo HSCT), with intervention both postransplant cyclophosphamide as GvHD prophylaxis, using a database with information from historical clinic data.
Detailed description
The overall aim of the study is to to analize CMVi after PTCy for GVHD prophylaxis, with a detailed description of CMVi and recurrences, direct and indirect consequences, in a HSCT population comparing two cohorts: haploidentical HSCT vs no haploidentical HSCT
Conditions
Timeline
- Start date
- 2020-02-14
- Primary completion
- 2020-03-17
- Completion
- 2020-12-17
- First posted
- 2022-04-07
- Last updated
- 2022-04-07
Locations
1 site across 1 country: Spain
Source: ClinicalTrials.gov record NCT05315882. Inclusion in this directory is not an endorsement.